J Dig Cancer Res.
2024 Dec;12(3):184-194. 10.52927/jdcr.2024.12.3.184.
Metabolic Dysfunction-associated Steatotic Liver Disease– related Hepatocellular Carcinoma: Current Research Insights
- Affiliations
-
- 1Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea
- 2Department of Internal Medicine, Ewha Womans University Medical Center, Seoul, Korea
- KMID: 2563743
- DOI: http://doi.org/10.52927/jdcr.2024.12.3.184
Abstract
- The global increase in the incidence of metabolic disorders is increasing the burden of nonalcoholic fatty liver disease (NAFLD) progression and NAFLD-related hepatocellular carcinoma (HCC) development; urgent measures are required to reduce this burden. The metabolic aspects of NAFLD led to the proposal to rename this condition as metabolic dysfunction-associated steatotic liver disease (MASLD). Diagnosis of MASLD, unlike that of NAFLD, requires the presence of at least one cardiometabolic risk factor (CMRF), creating a new focus on these factors, although the vast majority of patients with NAFLD meet the criteria for MASLD. In this article, we therefore review the current understanding of MASLD-related HCC, such as the epidemiology, risk factors with a particular focus on CMRFs, surveillance strategies, and risk stratification models.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Thyroid Hormone-Mediated Selective Autophagy and Its Implications in Countering Metabolic Dysfunction-Associated Steatotic Liver Disease
- Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review
- Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
- Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
- A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
